CanniMed Ltd. was established in 2013 to provide Canadian patients with access to a standardized and trusted supply of pharmaceutical-grade cannabis under the Marihuana for Medical Purposes Regulations (MMPR) governed by Health Canada.
CanniMed was the first producer to be licensed under the new regulations and is leading the industry as a result of the company’s deep history as the sole supplier to Health Canada under the previous MMAR program.
CanniMed is leading the way as a result of the company’s core commitments:
With 14 years of experience, the pharmaceutical-grade cannabis is produced under Good Manufacturing Practices (GMP) regulations, the criteria used to manufacture all pharmaceuticals in Canada.
As a result of growing under strict GMP regulations, patients can trust the consistency of the CanniMed products.
Patient safety is the company’s primary concern and as a result has developed procedures and processes, including strictly following a 281 point quality control process, to ensure consistency of our product for Canadian patients.
A strong corporate priority to design and execute clinical research that will close the gap between the anecdotal benefit and evidence based medicine in order to standardize care. Recruitment has begun on the CAPRI Trial (Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee), a randomized, double blind, placebo controlled, proof-of-concept, crossover clinical trial of single dose vaporized cannabis in adults with painful osteoarthritis of the knee.
CanniMed’s Canadian-grown cannabis is already leading the way in standardizing care and has been used in a published clinical trial demonstrating the efficacy of smoked cannabis for chronic paini, which was used in the development of the Canadian Pain Society’s Pharmacological management of chronic neuropathic pain: Revised consensus statement positioning medical cannabis as third line treatment for neuropathic painii.
With a team of field representatives, CanniMed’s leading education programs are helping physicians gain control and comfort in prescribing to patients.
CanniMed Care Program
The most comprehensive and straightforward patient appreciation initiative currently offered by any Canadian Licensed Producer. The Program includes patient direct pricing, renewal rewards and a patient newsletter. And for the Veterans, the program includes initial financing during the standard VA Canada waiting period, online ordering and veterans rewards.
In a recent patient satisfaction survey completed by hundreds of CanniMed patients, 97% said they would recommend CanniMed to others. (77% “Extremely Likely”; 19% “Likely”)
CanniMed is committed to helping people with chronic and terminal illnesses improve their quality of life when conventional medicine just isn’t enough.
i Ware, M.A., Wang, T., Shapiro, S., Robinson, A. and others. (2010) Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial. Canadian Medical Association Journal (CMAJ). 182:E694-E701.
ii Moulin, D.E., Boulanger, A., Clark A.J., Dao, T. and others. (2014) Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society. Pain Research and Management. Nov-Dec; 19(6): 328–335.